| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2012 | FOX CHASE CANCER CENTER | 333 COTTMAN AVE | PHILADELPHIA | PA | 19111-2497 | PHILADELPHIA | USA | U10CA027525 | Eastern Cooperative Oncology Group | 000 | 34 | NIH | 5/8/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $0 ) |
| | 2016 | 2008 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R01FD003017 | A phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard | 002 | 3 | FDA | 3/15/2016 | $0 |
| | 2016 | 2008 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R01FD003017 | A phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard | 001 | 3 | FDA | 2/19/2016 | $0 |
| | 2016 | 2007 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R01FD003017 | A phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard | 000 | 2 | FDA | 12/28/2015 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = -$195,961 ) |
| | 2014 | 2013 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | K22CA160725 | Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy | 001 | 3 | NIH | 1/2/2014 | -$195,961 |
| | 2014 | 2009 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R01FD003017 | A phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard | 000 | 4 | FDA | 12/31/2013 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $253,024 ) |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | U10CA027525 | Eastern Cooperative Oncology Group | 004 | 35 | NIH | 9/6/2013 | -$362,721 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVENUE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R21AG040366 | AGING FEATURES IN MICE WITH CONDITIONAL EXPRESSION OF P16INK4A | 001 | 2 | NIH | 5/23/2013 | $12,049 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | U10CA027525 | Eastern Cooperative Oncology Group | 002 | 35 | NIH | 8/6/2013 | $362,721 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | K22CA160725 | Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy | 003 | 3 | NIH | 8/15/2013 | $0 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | K22CA160725 | Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy | 006 | 3 | NIH | 1/2/2014 | -$195,961 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | K22CA160725 | Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy | 002 | 3 | NIH | 8/12/2013 | $195,961 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | K22CA160725 | Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy | 000 | 3 | NIH | 6/11/2013 | $195,961 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | U10CA027525 | Eastern Cooperative Oncology Group | 001 | 35 | NIH | 7/31/2013 | -$76,171 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | U10CA027525 | Eastern Cooperative Oncology Group | 000 | 35 | NIH | 5/16/2013 | $76,171 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | U10CA027525 | Eastern Cooperative Oncology Group | 005 | 35 | NIH | 9/11/2013 | $0 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | K22CA160725 | Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy | 005 | 3 | NIH | 9/5/2013 | $0 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | K22CA160725 | Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy | 001 | 3 | NIH | 7/24/2013 | -$195,961 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | U10CA027525 | Eastern Cooperative Oncology Group | 003 | 35 | NIH | 8/7/2013 | $0 |
| | 2013 | 2013 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVENUE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R21AG040366 | AGING FEATURES IN MICE WITH CONDITIONAL EXPRESSION OF P16INK4A | 000 | 2 | NIH | 5/3/2013 | $240,975 |
| | 2013 | 2011 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R01CA118159 | DEFINING THE ROLE OF AFFINITY IN ANTIBODY-BASED TUMOR TARGETING AND PENETRATION | 000 | 5 | NIH | 12/28/2012 | $0 |
| | 2013 | 2009 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R01CA106606 | DIET AND BREAST DENSITY OVER TIME IN US CHINESE WOMEN | 000 | 5 | NIH | 12/27/2012 | $0 |
| | 2013 | 2009 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 000 | 47 | NIH | 10/29/2012 | $0 |
| | 2013 | 2009 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R03CA135689 | ISOFLAVONES, EQUOL PRODUCING STATUS, AND BREAST DENSITY IN US CHINESE WOMEN | 000 | 2 | NIH | 10/25/2012 | $0 |
| | 2013 | 2009 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R01CA106606 | DIET AND BREAST DENSITY OVER TIME IN US CHINESE WOMEN | 001 | 5 | NIH | 12/27/2012 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $15,803,786 ) (Continued on the next page) |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 002 | 49 | NIH | 9/10/2012 | $140,000 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVENUE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R21AG040366 | AGING FEATURES IN MICE WITH CONDITIONAL EXPRESSION OF P16INK4A | 000 | 1 | NIH | 4/9/2012 | $222,813 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 004 | 49 | NIH | 9/13/2012 | $75,000 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVENUE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | K99CA158065 | ZNF-MEDIATED RESISTANCE TO IMATINIB MESYLATE IN GASTROINTESTINAL STROMAL TUMOR | 000 | 1 | NIH | 8/15/2012 | $100,961 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | R01CA134463 | THERAPEUTICS OF XIAP DEGRADATION BY ZINC CHELATORS | 000 | 4 | NIH | 4/25/2012 | $323,055 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 000 | 49 | NIH | 5/25/2012 | $4,061,662 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVENUE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | K01HS019001 | MyHealthPortal: Using An Electronic Portal To Empower Patients With Breast Cancer | 001 | 2 | AHRQ | 7/31/2012 | $146,254 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVENUE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R01CA136596 | THE ROLE OF HEF1 IN OVARIAN CANCER DEVELOPMENT, PROGRESSION, AND METASTASIS | 000 | 4 | NIH | 4/16/2012 | $323,047 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | P50CA083638 | FCCC-PENN SPORE IN OVARIAN CANCER | 001 | 14 | NIH | 9/20/2012 | $575,000 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVENUE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R01CA151374 | Evaluation of In Vivo Optical Imaging in Pancreatic and Ovarian Cancer Patients | 000 | 3 | NIH | 9/18/2012 | $426,421 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | R01CA077429 | BASIS FOR LYMPHOMAGENESIS IN AKT2 TRANSGENIC MICE | 000 | 13 | NIH | 11/16/2011 | $376,794 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | R01CA158019 | RCT of an Online Multimedia Program to Boost Coping & Function for Pca Survivors | 000 | 2 | NIH | 5/29/2012 | $708,941 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | U10CA027525 | Eastern Cooperative Oncology Group | 000 | 34 | NIH | 5/10/2012 | $319,919 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVENUE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R13MD007156 | AFRICAN-CARIBBEAN CANCER CONSORTIUM SCIENTIFIC AND TRAINING CONFERENCE | 000 | 2 | NIH | 6/21/2012 | $50,000 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVENUE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R03CA167671 | PIPERLONGUMINE: A NOVEL INHIBITOR OF ANDROGEN RECEPTOR SIGNALING | 000 | 1 | NIH | 7/9/2012 | $89,250 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | F32CA144199 | THE ROLE OF CYP1B1 IN THE RECURRENCE OF HEAD AND NECK CANCER | 000 | 2 | NIH | 11/29/2011 | $56,750 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | K22CA160725 | Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy | 000 | 2 | NIH | 6/21/2012 | $197,098 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | R01CA077429 | BASIS FOR LYMPHOMAGENESIS IN AKT2 TRANSGENIC MICE | 001 | 13 | NIH | 4/20/2012 | $33,657 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 7701 BURHOLME AVENUE | PHILADELPHIA | PA | 19111 | PHILADELPHIA | USA | R01CA131024 | THE ROLE OF METHYLTHIOADENOSINE PHOSPHORYLASE LOSS IN TUMORIGENESIS | 000 | 4 | NIH | 3/21/2012 | $358,605 |
| | 2012 | 2012 | FOX CHASE CANCER CENTER | 333 Cottman Ave | Philadelphia | PA | 19111-2434 | PHILADELPHIA | USA | P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 001 | 49 | NIH | 9/7/2012 | $115,518 |
|
